Thursday, July 14, 2011 7:16:46 PM
SNGX.ob - Do your DD -
12 July, 10 Hot Bio-tech stocks (The Street):
"Soligenix(SNGX.OB)
The event: Phase III study of orBec in graft-versus-host disease.
The timeline: Top-line results expected in the second half of the year.
The stakes: FDA rejected orBec in 2007, instructing Soligenix to run a confirmatory, phase III study in graft-versus-host disease (GVHD). OrBec is an oral (pill) reformulation of a well-known topical steroid that can be delivered directly to the gut, where it's most needed to help patients with GI GVHD."
Phase III study due this year, although as you see from above, the pill was previously rejected. If approved, share prices of $1.50 to $2.50 reported. Keep it on your watch list.
8K PM today - Two top Execs. give up bonuses for performance pay instead. Up 14% today likely on i2 July article and on 8K news leak.
47% ownership by insiders.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM